1
|
Moyret-Lalle C, Drouet Y, Treilleux I, Léon S, Viari A, Devouassoux-Shisheboran M, Voirin N, De la Fouchardiere C, Puisieux A, Lasset C. PO-226 Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
2
|
Moyret-Lalle C, Ruiz E, Bardel C, Treilleux I, Courtois-Cox S, Puisieux A. Specific EMT-inducers signature associates with oncogenic events in breast tumour progression. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61228-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
3
|
Moyret-Lalle C, Vitton-Méa B, Ruiz E, Hermann C, Lam E, Puisieux A. 164: Interplay between EMT-inducers and miRNAs during breast tumorigenesis. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50137-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Moyret-Lalle C, Ruiz E, Courtois-Cox S, Bardel C, Veron A. 162: Specific EMT-inducers signature associates with oncogenic events in breast tumour progression. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50135-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Ruiz E, Courtois-Cox S, Ansieau S, Puisieux A, Moyret-Lalle C. 434 Embryonic Transcription Factors, MiRNAs and Mitogenic Stresses Network in Breast Tumorigenesis – Deciphering the Interactome. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71112-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Hinkal GW, Grelier G, Puisieux A, Moyret-Lalle C. Complexity in the regulation of Dicer expression: Dicer variant proteins are differentially expressed in epithelial and mesenchymal breast cancer cells and decreased during EMT. Br J Cancer 2010; 104:387-8. [PMID: 21119658 PMCID: PMC3031887 DOI: 10.1038/sj.bjc.6606022] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
7
|
Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, Treilleux I, Léon-Goddard S, Rimokh R, Mikaelian I, Venoux C, Puisieux A, Lasset C, Moyret-Lalle C. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer 2009; 101:673-83. [PMID: 19672267 PMCID: PMC2736830 DOI: 10.1038/sj.bjc.6605193] [Citation(s) in RCA: 158] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2009] [Revised: 06/21/2009] [Accepted: 06/30/2009] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Dicer, a ribonuclease, is the key enzyme required for the biogenesis of microRNAs and small interfering RNAs and is essential for both mammalian development and cell differentiation. Recent evidence indicates that Dicer may also be involved in tumourigenesis. However, no studies have examined the clinical significance of Dicer at both the RNA and the protein levels in breast cancer. METHODS In this study, the biological and prognostic value of Dicer expression was assessed in breast cancer cell lines, breast cancer progression cellular models, and in two well-characterised sets of breast carcinoma samples obtained from patients with long-term follow-up using tissue microarrays and quantitative reverse transcription-PCR. RESULTS We have found that Dicer protein expression is significantly associated with hormone receptor status and cancer subtype in breast tumours (ER P=0.008; PR P=0.019; cancer subtype P=0.023, luminal A P=0.0174). Dicer mRNA expression appeared to have an independent prognostic impact in metastatic disease (hazard ratio=3.36, P=0.0032). In the breast cancer cell lines, lower Dicer expression was found in cells harbouring a mesenchymal phenotype and in metastatic bone derivatives of a breast cancer cell line. These findings suggest that the downregulation of Dicer expression may be related to the metastatic spread of tumours. CONCLUSION Assessment of Dicer expression may facilitate prediction of distant metastases for patients suffering from breast cancer.
Collapse
Affiliation(s)
- G Grelier
- Université de Lyon, Université Lyon 1, ISPB, Lyon, F-69003, France
- Inserm, U590, Lyon, F-69008, France
- Centre Léon Bérard, Lyon, F-69008, France
| | - N Voirin
- Université de Lyon, Université Lyon 1, Faculté Grange Blanche, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon, F-69373, France
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d’Hygiène, Epidémiologie et Prévention, Lyon, F-69437, France
| | - A-S Ay
- Université de Lyon, Université Lyon 1, ISPB, Lyon, F-69003, France
- Inserm, U590, Lyon, F-69008, France
- Centre Léon Bérard, Lyon, F-69008, France
| | - D G Cox
- Inserm, U590, Lyon, F-69008, France
| | - S Chabaud
- Centre Léon Bérard, Département de Santé Publique, Lyon, F-69008, France
| | - I Treilleux
- Centre Léon Bérard, Service d’Anatomopathologie, Lyon, F-69008, France
| | - S Léon-Goddard
- Centre Léon Bérard, Service d’Anatomopathologie, Lyon, F-69008, France
| | - R Rimokh
- Inserm, U590, Lyon, F-69008, France
- Centre Léon Bérard, Lyon, F-69008, France
| | - I Mikaelian
- Université de Lyon, université Lyon 1, Faculté Grange Blanche, CNRS, UMR5201, Laboratoire de Génétique Moléculaire, Signalisation et Cancer, Lyon, F-69008, France
| | - C Venoux
- Université de Lyon, université Lyon 1, Faculté Grange Blanche, CNRS, UMR5201, Laboratoire de Génétique Moléculaire, Signalisation et Cancer, Lyon, F-69008, France
| | - A Puisieux
- Université de Lyon, Université Lyon 1, ISPB, Lyon, F-69003, France
- Inserm, U590, Lyon, F-69008, France
- Centre Léon Bérard, Lyon, F-69008, France
| | - C Lasset
- Université de Lyon, Université Lyon 1, Faculté Grange Blanche, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon, F-69373, France
- Centre Léon Bérard, Département de Santé Publique, Lyon, F-69008, France
| | - C Moyret-Lalle
- Université de Lyon, Université Lyon 1, ISPB, Lyon, F-69003, France
- Inserm, U590, Lyon, F-69008, France
- Centre Léon Bérard, Lyon, F-69008, France
| |
Collapse
|
8
|
Moyret-Lalle C, Duriez C, Van Kerckhove J, Gilbert C, Wang Q, Puisieux A. p53 induction prevents accumulation of aberrant transcripts in cancer cells. Cancer Res 2001; 61:486-8. [PMID: 11212237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Loss of fidelity of the splicing process occurs during tumor progression and can have a deleterious effect on genes like tumor suppressor genes. It was reported recently that the presence of aberrant transcripts of the TSG101 gene in breast cancer cells was associated with the mutation of the p53 tumor suppressor gene. On the basis of this observation, we have analyzed TSG101 transcript patterns in p53-active and p53-inactive cells. Using several isogenic cellular models, we demonstrate that the induction of p53 in cancer cells leads to a significant decrease of aberrant transcripts levels. This indicates a novel implication of p53 in the regulation of the splicing process.
Collapse
Affiliation(s)
- C Moyret-Lalle
- Département d'Oncologie Fondamentale et Appliquée, INSERM Unité 453, Centre Léon Bérard, Lyon, France
| | | | | | | | | | | |
Collapse
|
9
|
Duriez C, Falette N, Cortes U, Moyret-Lalle C, Puisieux A. Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage. Oncogene 2000; 19:2461-4. [PMID: 10828889 DOI: 10.1038/sj.onc.1203580] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The p53 tumor suppressor protein functions to monitor the integrity of the genome. If a damage is detected, p53 binds tightly to specific sequence elements in the DNA and induces the transactivation of genes involved in various growth regulatory processes such as cell cycle progression, DNA repair and apoptosis. A p53-binding site was recently identified in the promoter region of the metastatic suppressor KAI1 gene, suggesting that this gene was a direct transcriptional target of p53. To test the relevance of this hypothesis, we studied the endogenous KAI1 expression in a series of human cell lines with varying p53 status in response to genotoxic treatment as well as in different cellular models exhibiting an inducible p53 activity. Overall, our data indicate that KAI1 expression is not significantly modulated by p53. This observation provides a direct evidence that the presence of a p53-binding site in regulatory domains is not a sufficient criteria to define a p53-transcriptional target gene.
Collapse
Affiliation(s)
- C Duriez
- Département d'Oncologie Fondamentale et Appliquée, INSERM Unité 453. Centre Léon Bérard, 28 rue Laënnec, 69008, Lyon, France
| | | | | | | | | |
Collapse
|
10
|
Cortes U, Moyret-Lalle C, Falette N, Duriez C, Ghissassi FE, Barnas C, Morel AP, Hainaut P, Magaud JP, Puisieux A. BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog 2000; 27:57-64. [PMID: 10657898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Exposure of mammalian cells to genotoxic agents evokes a complex cellular response. An ordered series of molecular events is necessary to sense DNA damage, transduce the signal, and ultimately delay the cell cycle or trigger apoptosis. Recently, we have shown that BTG2/TIS21 gene expression was induced in response to DNA damage through a p53-dependent pathway. This gene belongs to a newly identified family of structurally related genes whose other known human members are BTG1, BTG3, and Tob. To define the respective involvement of these four related genes in the cellular response to DNA damage, we studied their expression in human cell lines after a variety of genotoxic treatments. Our results demonstrated that were BTG1, BTG2/TIS21, and Tob genes the DNA damage--inducible genes. However, BTG2/TIS21 appeared to be the only p53-transcriptional target gene. We speculate that BTG proteins may play a coordinate role in a general transduction pathway that is induced in response to DNA damage. It has been previously described that recombinant BTG1 and BTG2/TIS21 can physically interact with PRMT1, an arginine methyl transferase, suggesting that BTG1 and BTG2/TIS21 induction may lead to posttranslational modifications of cellular proteins. In support of this hypothesis, we showed that the endogenous induction of BTG1 and BTG2 after genotoxic treatment was correlated with a modulation of protein methylation.
Collapse
Affiliation(s)
- U Cortes
- INSERM U453 and Unité d'Oncologie Moléculaire, Centre Léon Bérard, Lyon, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Cai Z, Capoulade C, Moyret-Lalle C, Amor-Gueret M, Feunteun J, Larsen AK, Paillerets BB, Chouaib S. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene 1997; 15:2817-26. [PMID: 9419972 DOI: 10.1038/sj.onc.1201445] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We have investigated the relationship between the development of tumor resistance towards the cytotoxic action of tumor necrosis factor-alpha (TNF) and p53 function, using the TNF-sensitive MCF7 human breast adenocarcinoma cell line and two TNF-resistant sublines, MCF7/R-A1 and MCF7/Adr. Use of single-strand conformation polymorphism (SSCP) analysis and DNA sequencing shows that MCF7 has a wild-type p53 gene, whereas both TNF-resistant sublines exhibit mutant p53. This includes a point mutation R280K in MCF7/R-A1 cells, and a point mutation at the splicing acceptor site on the upstream border of exon 5 resulting in a 21 pb deletion in MCF7/Adr cells. These mutations result in loss of p53 capacity to transactivate FASAY (functional assay in yeast). In contrast to what is observed for parental MCF7 cells, treatment of resistant sublines with TNF or gamma-irradiation fails neither to induce the expression of the p53-regulated gene products p21waf1/CIP1 and MDM2, nor to arrest the cells in the G1 phase of the cell cycle. Disruption of p53 wild-type function in MCF7 cells by transfection with human papillomavirus type-16 E6 gene, leads to abrogation of the cytotoxic, but not the cytostatic activity of TNF. Altogether, our results strongly suggest that wild-type p53 is involved in cytotoxic action of TNF, and point out that loss of p53 function contributes to resistance of tumor cell to TNF-induced killing.
Collapse
Affiliation(s)
- Z Cai
- INSERM CJF 94-11 Cytokines et Immunité Antitumorale, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Pedeux R, Branche R, Moyret-Lalle C, Ozturk M, Dor?? JF. Apoptosis induction and cell cycle changes in human melanoma cells following UV-C or UV-B irradiation. Melanoma Res 1997. [DOI: 10.1097/00008390-199706001-00315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Rouault JP, Falette N, Guéhenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R, Samarut J, Magaud JP, Ozturk M, Samarut C, Puisieux A. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 1996; 14:482-6. [PMID: 8944033 DOI: 10.1038/ng1296-482] [Citation(s) in RCA: 330] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Cell cycle regulation is critical for maintenance of genome integrity. A prominent factor that guarantees genomic stability of cells is p53 (ref. 1). The P53 gene encodes a transcription factor that has a role as a tumour suppressor. Identification of p53-target genes should provide greater insight into the molecular mechanisms that mediate the tumour suppressor activities of p53. The rodent Pc3/Tis21 gene was initially described as an immediate early gene induced by tumour promoters and growth factors in PC12 and Swiss 3T3 cells. It is expressed in a variety of cell and tissue types and encodes a remarkably labile protein. Pc3/Tis21 has a strong sequence similarity to the human antiproliferative BTG1 gene cloned from a chromosomal translocation of a B-cell chronic lymphocytic leukaemia. This similarity led us to speculate that BTG1 and the putative human homologue of Pc3/Tis21 (named BTG2) were members of a new family of genes involved in growth control and/or differentiation. This hypothesis was recently strengthened by the identification of a new antiproliferative protein, named TOB, which shares sequence similarity with BTG1 and PC3/TIS21 (ref. 7). Here, we cloned and localized the human BTG2 gene. We show that BTG2 expression is induced through a p53-dependent mechanism and that BTG2 function may be relevant to cell cycle control and cellular response to DNA damage.
Collapse
Affiliation(s)
- J P Rouault
- Unité INSERM U453, Affiliée au CNRS, Centre Léon Bérard, Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Lalle P, Moyret-Lalle C, Wang Q, Vialle JM, Navarro C, Bressac-de Paillerets B, Magaud JP, Ozturk M. Genomic stability and wild-type p53 function of lymphoblastoid cells with germ-line p53 mutation. Oncogene 1995; 10:2447-54. [PMID: 7784096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Increased cancer risk associated with germ-line p53 mutation was linked to a deficit in the ability to maintain genomic stability. Accordingly, normal fibroblasts from cancer-prone individuals accumulate genomic aberrations with concomitant loss of wild-type p53 allele during in vitro culture. We tested whether such changes also occur in EBV-immortalized lymphoblastoid cells. Both normal and p53 germ-line mutant lymphoblastoid cells maintained functional p53 and genomic stability during long term in vitro culture. These unexpected differences between fibroblastic and lymphoblastic cells suggest that phenotypic expression of p53 deficiency is cell type specific. This could contribute to selective tissular localization of tumours observed in patients with Li-Fraumeni syndrome despite the presence of a mutant p53 allele in all cells.
Collapse
Affiliation(s)
- P Lalle
- Laboratoire d'oncologie moléculaire, INSERM CJF9302, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Moyret-Lalle C, Marçais C, Jacquemier J, Moles JP, Daver A, Soret JY, Jeanteur P, Ozturk M, Theillet C. ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995; 64:124-9. [PMID: 7542226 DOI: 10.1002/ijc.2910640209] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
To study the role of ras, p53 genes and HPV virus (16 and 18) in the development of prostate cancer, we analyzed tissue sections from 27 patients affected with carcinomas (stages A to D) and from 24 patients with adenomas. Mutations of H, K and N-ras and p53 (exons 2-9) were studied by SSCP and DNA sequencing. Accumulation of p53 protein was studied by immunohistochemistry on tissue sections. Tumors were also analyzed for the presence of HPV16 and -18 sequences by PCR and DNA hybridization with sequence-specific oligonucleotides. No mutation was found in the three ras genes studied, either in carcinomas or adenomas. By SSCP analysis we identified p53 mutations in only 2 of 19 carcinomas studied, both in exon 7. Immunohistochemical results strongly correlate with the SSCP results: p53 protein was positive in tumors with p53 mutation but not in others; 32% of studied adenomas had detectable HPV16 DNA, while 53% of carcinomas were HPV16+. Among these I presented a p53 mutation. No HPV18 E6 sequence could be detected. Our data show that in prostate tumors from France, mutations of p53 and ras are rare events but that these tumors display detectable HPV16 DNA at a high frequency. The low incidence of p53 mutation, associated to a significant proportion of tumors showing HPV16 DNA, could suggest that in prostate cancer HPV16 infection could participate in p53 inactivation by E6.
Collapse
Affiliation(s)
- C Moyret-Lalle
- Institut de Génétique Moléculaire de Montpellier, France
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Mazoyer S, Lalle P, Moyret-Lalle C, Marçais C, Schraub S, Frappaz D, Sobol H, Ozturk M. Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations. Oncogene 1994; 9:1237-9. [PMID: 8134127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Codon 257 of the p53 gene is an extremely rare target for somatic mutations (accounting for only two of 1600 published mutations). We report here two constitutional mutations both affecting the second nucleotide of codon 257. A thymine to adenine transversion resulting in an amino acid change from leucine to glutamine was found in one proband who developed multiple independent malignant tumors (osteosarcoma, phyllodes tumor, soft-tissue sarcoma). Her mother died of early-onset breast cancer. In the other case, a deletion resulting in a frameshift in the C-terminal coding region of p53 was found in a woman who was diagnosed with breast cancer at age 34. This woman belongs to a family with features of Li-Fraumeni syndrome. In both cases, the p53 mutations identified in the proband was found in other members of the family. Codon 257, even if rarely mutated in somatic cells, may thus be an important target for germ-line mutations.
Collapse
Affiliation(s)
- S Mazoyer
- Laboratoire d'Oncologie Moléculaire--CJF INSERM 9302, Centre Léon Bérard, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|